Document is current
Any future updates will be listed below
-
Authors
Grassl, Niklas http://orcid.org/0000-0001-7987-0444
Sahm, Katharina
Süße, Heike
Poschke, Isabel
Bunse, Lukas
Bunse, Theresa
Boschert, Tamara
Mildenberger, Iris
Rupp, Anne-Kathleen
Ewinger, Max Philipp
Lanz, Lisa-Marie
Denk, Monika
Tabatabai, Ghazaleh
Ronellenfitsch, Michael W.
Herrlinger, Ulrich
Glas, Martin
Krex, Dietmar
Vajkoczy, Peter
Wick, Antje
Harting, Inga
Sahm, Felix
von Deimling, Andreas
Bendszus, Martin
Wick, Wolfgang
Platten, Michael http://orcid.org/0000-0002-4746-887X
-
Funding
Funding for this research was provided by:
Gemeinnützige Hertie-Stiftung (P1200013)
Deutsche Forschungsgemeinschaft (EB 187/8-1, 445549683, 39404578, 445549683, 39404578)
Deutsche Krebshilfe (70113456)
- License Information
-
More Information
Article History
Received: 12 September 2023
Accepted: 13 September 2023
First Online: 19 October 2023
Declarations
:
: The study was approved by the national regulatory authority (Paul-Ehrlich Institute, Germany) and the institutional review boards (Ethikkommissionen) at each initiated study site.
: Not applicable.
: MP is founder of Tcelltech GmbH and inventor of associated intellectual property related to glioma-reactive T cell receptors (patent number: WO2022200456A1). MP, KS, LB, TB and WW are inventors of associated intellectual property related to H3K27M vaccines (patent numbers: EP3118217A1, US20180155403A1). TB, EWG, MP, and KS are listed as inventors on a patent application describing K27M specific antibodies. GhT has served on advisory boards (Bayer, Boehringer Ingelheim, CureVac, Novocure), as a consultant (Bayer, Boehringer Ingelheim, CureVac), as steering committee member in non-interventional trials (Bayer, Novocure) and financial compensation for all these activities was provided as institutional funding to the University Hospital Tübingen. UH received speakers and/or advisory board honoraria from Medac, Janssen and Bayer. GhT, WW and MP are Editorial Board Members of Neurological Research and Practice. The remaining authors declare no competing interests.
